ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2006
Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies.Molecular therapy. Oncology · 2026Article
- Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.Journal of thoracic disease · 2018Review
- Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs.Clinical and translational medicine · 2017Article
- Oncolytic virotherapy for human malignant mesothelioma: recent advances.Oncolytic virotherapy · 2015Review
- Regional delivery of oncolytic vaccinia virus: it's time for clinical trials.Annals of surgical oncology · 2014Article
- Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus.Cancer gene therapy · 2013Article
- Is survivin expression prognostic or predictive in malignant pleural mesothelioma?Virchows Archiv : an international journal of pathology · 2013Article
- Gene therapy for malignant mesothelioma: current prospects and challenges.Cancer gene therapy · 2013Review
- A potential therapeutic strategy for malignant mesothelioma with gene medicine.BioMed research international · 2013Review
- BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.Journal of cancer research and clinical oncology · 2011Article
- Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma.Cancer gene therapy · 2011Article
- Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus.The journal of gene medicine · 2010Article
- Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax.Cancer gene therapy · 2010Article
- Gene therapy of benign gynecological diseases.Advanced drug delivery reviews · 2009Review
- Correlation between the levels of survivin and survivin promoter-driven gene expression in cancer and non-cancer cells.Cellular & molecular biology letters · 2009Article
- Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy.Molecular therapy : the journal of the American Society of Gene Therapy · 2008Article
- Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells.Cancer research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Mesothelioma is a highly malignant neoplasm with no effective treatment. Conditionally replicative adenoviruses (CRAds) represent a promising new modality for the treatment of cancer in general. A key contribution in this regard is the introduction of tumor-selective viral replication for amplification of the initial inoculum in the neoplastic cell population. Under ideal conditions following cellular infection, the viruses replicate selectively in the infected tumor cells and kill the cells by cytolysis, leaving normal cells unaffected. However, to date there have been two limitations to clinical application of these CRAd agents; viral infectivity and tumor specificity have been poor. Herein we report on two CRAd agents, CRAd-S.RGD and CRAd-S.F5/3, in which the tumor specificity is regulated by a tumor-specific promoter, the survivin promoter, and the viral infectivity is enhanced by incorporating a capsid modification (RGD or F5/3) in the adenovirus fiber region. These CRAd agents effectively target human mesothelioma cell lines, induce strong cytoxicity in these cells in vitro, and viral replication in a H226 murine xenograft model in vivo. In addition, the survivin promoter has extremely low activity both in the non-transformed cell line, HMEC, and in human liver tissue. Our results suggest that the survivin-based CRAds are promising agents for targeting mesothelioma with low host toxicity. These agents should provide important insights into the identification of novel therapeutic strategies for mesothelioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.